P
ProLynx
Biotech & Life Sciences · Brentwood, United States · Founded 2009
Extending medicine impact with ultra-long-acting therapies MoreLess
ProLynx is an innovative biotechnology company focused on developing ultra-long-acting medicines to transform the treatment of obesity and related metabolic diseases. At the heart of ProLynx’s work is a proprietary half-life extension technology that enables therapeutic candidates to be dosed once monthly or once quarterly, offering a promising alternative to current therapies that require more frequent administration. This approach aims to improve treatment consistency, tolerability and patient outcomes by smoothing pharmacokinetic profiles and enhancing long-term adherence.
Headquartered in the San Francisco Bay Area, ProLynx advances a next-generation portfolio of extended-duration therapeutic programs while actively collaborating with top biotech investors and scientific partners. Backed by leading venture firms including 5AM Ventures, OrbiMed and Monograph Capital, the company recently secured a significant Series A financing to accelerate its pipeline and leadership team. With deep scientific roots and an emphasis on addressing unmet medical needs through novel drug delivery mechanisms, ProLynx is positioned to redefine the standards of care in metabolic disease therapeutics.
Company overview
ProLynx company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2009
- Headquarters
- Brentwood, United States
- Employees
- 34
- Open positions
- 4
- Dealroom signal
- 59.1
Valuation & funding
ProLynx funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Dec 2025 | $70M | $280M | Monograph Capital · 5AM Ventures · OrbiMed | ↗ |
| GRANTOther financing | Jul 2020 | $230K | — | National Institutes of Health | — |
| GRANTOther financing | Nov 2018 | $150K | — | National Institutes of Health | — |
| GRANTOther financing | Nov 2016 | $250K | — | US National Science Foundation | — |
| GRANTOther financing | Nov 2014 | $740K | — | US National Science Foundation | — |
| GRANTOther financing | Jan 2013 | US National Science Foundation | — | ||
| GRANTOther financing | Oct 2010 | National Institutes of Health | — | ||
| GRANTOther financing | May 2010 | National Institutes of Health | — |
Growth signals
ProLynx website traffic
Latest recorded traffic for ProLynx is 1.7K monthly website visits, up 2733.3% over the last three months. ProLynx's team grew 36% over the past year.
Hiring
Open positions at ProLynx
Current openings linked to this company in Dealroom.
Comparisons
ProLynx compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
ProLynx's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where ProLynx has talent and traffic
team presence
In the news
Latest news about ProLynx
Recent press, funding announcements, and product moves mentioning ProLynx — open to read from the original sources.
Market sentiment
What the market is saying about ProLynx
An AI-synthesized read of the highest-engagement posts about ProLynx on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ProLynx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.